Gα(q) Antibody [C11L2]

Catalog No.: F7457

    Application: Reactivity:
    • Lane 1: 293T, Lane 2: HeLa, Lane 3: C6, Lane 4: RAW264.7
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:30
    1:1000
    Application
    WB, IP, IHC
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Rat, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    42 kDa 42 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    Gα(q) Antibody [C11L2] detects endogenous levels of total Gα(q) protein.
    Clone
    C11L2
    Synonym(s)
    GAQ, GNAQ, Guanine nucleotide-binding protein G(q) subunit alpha, Guanine nucleotide-binding protein alpha-q
    Background
    G protein subunit alpha q (GNAQ) is a ubiquitously expressed heterotrimeric G protein alpha subunit of the Gq/11 family that couples activated G protein–coupled receptors to phospholipase C‑β–dependent phosphoinositide signaling and calcium mobilization, with prominent roles in vascular, hematopoietic, and neural tissues. The protein contains a canonical GTP‑binding domain with switch regions that undergo conformational changes upon GDP–GTP exchange, an N‑terminal segment that contributes to membrane association and interaction with Gβγ, and C‑terminal residues that recognize activated GPCRs and determine receptor coupling specificity. Activation begins when a ligand‑bound seven‑transmembrane receptor promotes GDP release from GNAQ and binding of GTP, which dissociates Gαq from Gβγ and positions the active GTP‑bound alpha subunit to engage downstream effectors, primarily phospholipase C‑β isoforms. Direct activation of PLC‑β by Gαq drives hydrolysis of phosphatidylinositol 4,5‑bisphosphate into inositol 1,4,5‑trisphosphate and diacylglycerol, triggering release of calcium from intracellular stores and activation of protein kinase C, and these second messengers converge on multiple pathways that regulate gene expression, cytoskeletal dynamics, proliferation, secretion, and contractility. Intrinsic GTPase activity of GNAQ, supported by regulatory proteins, converts GTP to GDP to terminate signaling and allows reassociation with Gβγ to reform the inactive heterotrimer, creating a tightly controlled cycle that links receptor occupancy to the duration and amplitude of phosphoinositide and calcium signaling. In vascular development and function, GNAQ participates in GPCR pathways that shape endothelial and smooth‑muscle behavior and contributes to regulation of vessel patterning, tone, and remodeling, while in the immune system it regulates B cell selection and survival, prevents B cell–dependent autoimmunity, and influences chemotaxis of myeloid cells through coupling to chemokine and lipid receptors. Roles in platelet activation arise from Gαq‑mediated coupling of thromboxane and other platelet GPCRs to PLC‑β activation and calcium‑dependent granule release and integrin activation, which makes GNAQ central to hemostatic and thrombotic responses. Pathogenic variants that impair GTP hydrolysis generate a constitutively active Gαq that remains locked in the GTP‑bound state, causing persistent downstream signaling with sustained PLC‑β activation, chronic calcium elevation, and PKC–MAPK pathway engagement. Somatic mutations affecting conserved residues such as Q209 and R183 occur frequently in uveal melanoma, blue nevi, and related melanocytic lesions, where constitutive GNAQ activation serves as an early oncogenic driver that promotes MAPK and YAP‑dependent transcriptional programs linked to proliferation and survival. Mosaic activating mutations in GNAQ underlie Sturge–Weber syndrome, in which chronic Gαq signaling disrupts normal regulation of blood vessel development and leads to abnormal capillary malformations, leptomeningeal vascular anomalies, and associated neurologic manifestations.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください